Monomethyl Fumarate
NSCLC (Advanced Non-small Cell Lung Cancer)
Wondercel Biotech (ShenZhen)Small moleculeEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the NSCLC (Advanced Non-small Cell Lung Cancer) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Jmkx001899 Jemincare | Phase 3 | B |
gfh375 Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | B |
Pucotenlimab Anhui Provincial Cancer Hospital | Phase 2/3 | B |
Tazemetostat Peking University Cancer Hospital & Institute | Phase 2 | B |
alk202 Shanghai Allink Biotherapeutics Co., Ltd. | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →